NASDAQ:CDT

CDT Equity Q4 2024 Earnings Results & Report

CDT Equity logo
$0.34 -0.03 (-8.49%)
As of 03:04 PM Eastern
This is a fair market value price provided by Massive. Learn more.

CDT Equity reported Q4 2024 earnings on March 28, 2025. The company reported EPS of -$304,950,000.00.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
After Market Closes

CDT Equity EPS Results

Actual EPS
-$304,950,000.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

CDT Equity Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

CDT Equity Q4 2024 Earnings FAQ

CDT Equity (NASDAQ:CDT) reported earnings of -$304,950,000.00 per share for Q4 2024. The report was announced on Friday, March 28, 2025.

CDT Equity Earnings Headlines

The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
CDT Equity Announces 1-for-20 Reverse Stock Split
See More CDT Equity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CDT Equity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CDT Equity and other key companies, straight to your email.

About CDT Equity

CDT Equity (NASDAQ:CDT) (NASDAQ: CDT) is associated with the former Conduit Pharmaceuticals, a biotechnology company focused on developing drug candidates for diseases with unmet medical needs.

Conduit’s historical pipeline included compounds licensed from AstraZeneca, with research directed toward areas including inflammation and autoimmune disease. The company’s approach was to advance existing drug candidates rather than discover medicines entirely from scratch.

Conduit had operations and a corporate presence in the United Kingdom and the United States. Because the company’s name and business status have changed, its historical biotechnology activities may not fully describe CDT Equity’s current operations.

View CDT Equity Profile